结直肠癌血清中DLC1、p16和RUNX3基因甲基化检测的临床意义  

Clinical significance of detecting serum DLC1,p16 and RUNX3 gene methylation status in colorectal cancer

作　　者：邹继红[1] 吴平平[2] 汤日宁[1] 姚瑶[3] 尤承忠[4] 

机构地区：[1]东南大学附属中大医院内科,南京市210009 [2]江苏省肿瘤医院内科 [3]江苏省肿瘤医院普通外科 [4]东南大学附属中大医院普通外科,南京市210009

出　　处：《江苏医药》2011年第24期2938-2940,共3页Jiangsu Medical Journal

摘　　要：目的分析检测结直肠癌(CRC)患者血清肝癌缺失基因1(DLC1)、p16和RUNT相关转录因子3(RUNX3)基因甲基化状态的临床意义。方法留取85例CRC及45例肠道良性病变患者血清标本,甲基化特异性聚合酶链反应(MSP)检测基因启动子区域甲基化。结果 85例CRC血清中,DLC1、p16和RUNX3基因甲基化比例分别为42.4%(36/85)、44.7%(38/85)和34.1%(29/85),均显著高于良性病变组(P<0.01)。DLC1、p16和RUNX3基因甲基化与患者临床病理特征无相关性。三者联合检测可显著提高CRC检出率,并且特异性未降低。结论血清DLC1、p16和RUNX3甲基化可望成为CRC诊断的新型分子标记,三者联合可进一步提高诊断效能。Objective To analyze the clinical significance of detecting serum DLC1,p16 and RUNX3 gene methylation status in colorectal cancer（CRC）.Methods Genomic DNA was extracted from peripheral blood of 85 CRC patients and 45 controls with benign colorectal diseases.Promoter methylation status was determined by methylation-specific polymerase chain reaction（MSP）.ResultsSerum methylation frequences of DLC1,p16 and RUNX3 gene in CRC were 42.4%（36/85）,44.7%（38/85） and 34.1%（29/85）,respectively,which were all significantly higher than those in benign colorectal diseases（P0.01）.DLC1,p16 and RUNX3 gene rmethylation status was not correlated with clinicopathological parameters.Combined analysis of serum DLC1,p16 and RUNX3 methylation in CRC showed a higher sensitivity without reducing diagnostic specificity.Conclution Serum DLC1,p16 and RUNX3 methylation in CRC may become the new biomarkers for the diagnosis of CRC.Combined analysis of serum DLC1,p16 and RUNX3 methylation in CRC would improve the detectability efficiently.

关 键 词：结直肠癌 肝癌缺失基因1 P16 RUNT相关转录因子3 

分 类 号：R735[医药卫生—肿瘤]